ABLYNX TO PRESENT AT THE 35th ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
(Thomson Reuters ONE) -
GHENT, Belgium, 5 January 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY]
will present at the 35(th) Annual J.P. Morgan Healthcare Conference on Wednesday
11 January 2017 at 4:30 p.m. Pacific Standard Time (1.30 a.m. on Thursday 12
January, Central European Time).
The presentation will be given by Dr Edwin Moses, CEO of Ablynx, and a breakout
session will follow immediately.
The presentation will be webcast live and can be accessed on the day via this
link. To ensure a timely connection, it is recommended that users register at
least 10 minutes prior to the scheduled webcast. A replay of the webcast will
be available on the Company's website, under the news & events section, for 90
days following the presentation.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®,
proprietary therapeutic proteins based on single-domain antibody fragments,
which combine the advantages of conventional antibody drugs with some of the
features of small-molecule drugs. Ablynx is dedicated to creating new medicines
which will make a real difference to society. Today, the Company has more than
45 proprietary and partnered programmes in development in various therapeutic
areas including inflammation, haematology, immuno-oncology, oncology and
respiratory disease. The Company has collaborations with multiple pharmaceutical
companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck &
Co., Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho Pharmaceuticals. The
Company is headquartered in Ghent, Belgium. More information can be found on
www.ablynx.com.
For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses(at)ablynx.com
Marieke Vermeersch
Director IR & Corporate Communications
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch(at)ablynx.com
Follow us on Twitter (at)AblynxABLX
Ablynx media/analyst relations
FTI Consulting:
Julia Phillips, Brett Pollard, Mo Noonan, Matthew Moss
t: +44 20 3727 1000
e: ablynx(at)fticonsulting.com
pdf format of the press release:
http://hugin.info/137912/R/2068967/777067.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ablynx via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 05.01.2017 - 07:00 Uhr
Sprache: Deutsch
News-ID 515897
Anzahl Zeichen: 2961
contact information:
Town:
Ghent/Zwijnaarde
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 218 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ABLYNX TO PRESENT AT THE 35th ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
